A Phase 2 interventional study of L-menthol and Placebo in Asthma, sponsored by Region Skane. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Region Skane · Phase 2, Interventional, and Basic science
The purpose of this study is to assess the effect of L-menthol on breathlessness and exercise capacity in patients with Asthma.
Dyspnea is a cardinal symptom in patients with lung disease, often triggered by daily-life physical activities. To date, an effective pharmacologic treatment to relieve chronic dyspnea is lacking. Recent pilot data support that inhaled L-menthol can markedly decrease laboratory-induced dyspnea in COPD and ILD patients, likely through increased afferent feedback of airflow in the airways by inducing a cooling sensation through olfactory stimulation. The aim of this study is therefore to assess the effectiveness and mechanisms of inhaled menthol for relief of patients with Asthma.
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's planned enrollment of 20 is below the median of 78 across 3,341 interventional studies indexed under Asthma.
Browse Asthma studies →Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the trial, prior to performing submaximal cardio-pulmonary exercise testing (CPET), participants will be administered, L-menthol patch which will be attached to the inside of a facemask that is connected to the breathing circuit.
Drug: L-menthol
For placebo, the patch will contain a similarly patch with strawberry scent.
Other: Placebo
(Sigma-Aldrich, St. Louis, US)
Strawberry scent (Sigma-Aldrich, St. Louis, US)
Breathlessness intensity
The difference between treatment conditions in dyspnea intensity at iso-time. The Borg's modified 0-10 category ratio scale (Borg CR10) will be used, where 0 represents no perceived breathlessness at all, and 10 represents maximum breathlessness intensity ever experienced.
Time frame: During submaximal test, at isotime during day 2 and day 3.
Dyspnea unpleasantness
The difference between treatment conditions in dyspnea unpleasantness at iso-time. The Borg's modified 0-10 category ratio scale (Borg CR10) will be used, where 0 represents no perceived unpleasantness at all, and 10 represents maximum breathlessness unpleasantness experienced.
Time frame: During submaximal test, at iso-time during day 2 and day 3
Total time
Time to the limit of tolerance (s) (tLIM)
Time frame: At the end of submaximal test during day 2 and day 3.
Exercise capacity
V'O2 (aerobic exercise capacity, absolute and in %pred)
Time frame: Submaximal test during day 2 and day 3.
Peak dyspnea intensity
Dyspnea intensity at peak exercise. The Borg's modified 0-10 category ratio scale (Borg CR10) will be used, where 0 represents no perceived breathlessness at all, and 10 represents maximum breathlessness intensity ever experienced.
Time frame: During submaximal test, at peak during day 2 and day 3.
Leg fatigue
The Borg's modified 0-10 category ratio scale (Borg CR10) will be used, where 0 represents no perceived leg fatigue at all, and 10 represents maximum leg fatigue ever experienced.
Time frame: During submaximal test, at day 2 and day 3.
Ventilatory efficacy
Efficacy of ventilation (VE/V'CO2-slope)
Time frame: During submaximal test, at day 2 and day 3.
Saturation
O2-Saturation
Time frame: During submaximal test, at day 2 and day 3.
Stop reason
Causes of stopping the test
Time frame: During submaximal test, at day 2 and day 3.
Adverse events
Any adverse events during the test
Time frame: Through study completion, an average of 1 week.
Respiratory exchange ratio
Respiratory exchange ratio (RER), defined as V'CO2/V'O2
Time frame: During the submaximal test at day 2 and day 3.
Heart rate
Heart rate in beats/min
Time frame: During the submaximal test at day 2 and day 3.
Breathing frequency
Breathing frequency in breaths/min
Time frame: During the submaximal test at day 2 and day 3.
Minute ventilation
Ventilation per minute
Time frame: During the submaximal test at day 2 and day 3.
Tidal volume
Tidal volume in liters
Time frame: During the submaximal test at day 2 and day 3.
Ventilatory reserve
Defined as maximal voluntary ventilation (MVV) - VE
Time frame: During the submaximal test at day 2 and day 3.
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.
Of 61 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 11 months is below that.
Counting every sponsor, half of 198 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomenthol